GDC-0449: Phase II complete enrollment

Roche's Genentech unit completed enrollment of 100 patients in an open-label Phase II trial evaluating oral GDA-0449. Roche has exclusive ex-U.S. rights to GDC-0449 from Genentech, which is co-develop...